Press release
Diabetic Retinopathy Pipeline, Clinical Trials Assessment, NDA Approvals 2023 (Updated) | Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ing
Diabetic Retinopathy Pipeline
In the Diabetic Retinopathy pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Diabetic Retinopathy NDA approvals (if any), and product development activities comprising the technology, Diabetic Retinopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
To explore more information on the latest breakthroughs in the Diabetic Retinopathy pipeline treatment landscape of the report, click here @ Diabetic Retinopathy Pipeline Outlook- https://www.delveinsight.com/report-store/diabetic-retinopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Diabetic Retinopathy Pipeline Report
• DelveInsight's Diabetic Retinopathy Pipeline analysis depicts a robust space with 50+ active players working to develop 55+ pipeline treatment therapies.
• The leading Diabetic Retinopathy Companies working in the market include Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, and others.
• Promising Diabetic Retinopathy Pipeline Therapies in the various stages of development include OTT166, MS-R001 (rapamycin), Runcaciguat (BAY1101042), PDS Implant Pre-Filled with 100 mg/mL Ranibizumab, COLIRIOBCN070660, Brimonidine, OTX-TKI, OPL-0401 Dose 1, Octreotide Acetate in Microspheres 20 mg, and others
• On February 2023, EyePoint Pharmaceuticals Inc announced a study of phase 2 clinical trials for EYP-1901. A prospective, randomized, double-masked study evaluating the ocular efficacy and safety of two doses of the EYP-1901 intravitreal insert compared to sham.
• On May 2023, Hoffmann-La-Roche announced a study of phase 3 clinical trials for PDS Implant Pre-Filled with 100 mg/mL Ranibizumab and Intravitreal Ranibizumab 0.5 mg Injection. Study GR41675 is a Multicenter, Randomized Study in Participants with Diabetic Retinopathy (DR) Without Center-Involved Diabetic Macular Edema (CI-DME) to Evaluate the Efficacy, Safety of the Port Delivery System with Ranibizumab (PDS) Relative to the Comparator Arm.
• On July 2023, OcuTerra Therapeutics Inc announced a study of phase 2 clinical trials for OTT166. This study will evaluate the safety and efficacy of OTT166 Ophthalmic solution in participants with Diabetic Retinopathy.
• On July 2023, Bayer announced a study of phase 2 clinical trials for Runcaciguat (BAY1101042). This Phase 2 study is conducted to investigate the safety and efficacy of runcaciguat in the treatment of diabetic retinopathy. To assess efficacy, the retinal morphology will be investigated by 7-field color fundus photography for central assessment of the diabetic retinopathy severity score, or DRSS. Two-step DRSS improvement at 24 weeks of treatment will be the primary efficacy endpoint.
Diabetic Retinopathy Overview
Diabetic retinopathy (DR) is a major complication of diabetes mellitus (DM), which remains a leading cause of visual loss in working-age populations. The retina contains photoreceptor cells that function in the process of visual transduction, i.e., transforming light signals to nerve impulses eventually transmitted from the optic nerve to the brain forming an image.
To explore more information on the latest breakthroughs in the Diabetic Retinopathy Pipeline treatment landscape of the report, click here @- https://www.delveinsight.com/sample-request/diabetic-retinopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Diabetic Retinopathy Emerging Drugs Profile
• KSI-301: Kodiak Sciences
• Brolucizumab: Novartis
• RGX 314: Regenxbio Inc.
• OTT-166: OcuTerra Therapeutics
• OTX-TKI: Ocular Therapeutix
Diabetic Retinopathy Pipeline Therapeutics Assessment
There are approx. 50+ key companies which are developing the therapies for Diabetic Retinopathy. The Diabetic Retinopathy companies which have their Diabetic Retinopathy drug candidates in the most advanced stage, i.e. phase III include, Kodiak Sciences.
Request a sample and discover the recent advances in Diabetic Retinopathy Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/diabetic-retinopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Diabetic Retinopathy Drugs and Companies
• OTT166: Ocuterra Therapeutics Inc
• MS-R001 (rapamycin): Santen Inc
• Runcaciguat (BAY1101042): Bayer
• COLIRIOBCN070660: BCN Peptides
• OTX-TKI: Ocular Therapeutics Inc
Diabetic Retinopathy Therapeutics Assessment
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Some of the Companies in the Diabetic Retinopathy Therapeutics Market include-
Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, and others.
Dive deep into rich insights for drugs for Diabetic Retinopathy Pipeline, click here for O Diabetic Retinopathy Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/diabetic-retinopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Diabetic Retinopathy Pipeline Report
• Coverage- Global
• Diabetic Retinopathy Companies- Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, and others.
• Diabetic Retinopathy Pipeline Therapies- OTT166, MS-R001 (rapamycin), Runcaciguat (BAY1101042), PDS Implant Pre-Filled with 100 mg/mL Ranibizumab, COLIRIOBCN070660, Brimonidine, OTX-TKI, OPL-0401 Dose 1, Octreotide Acetate in Microspheres 20 mg, and others.
• Diabetic Retinopathy Pipeline Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Diabetic Retinopathy Mergers and acquisitions, Licensing Activities @ https://www.delveinsight.com/sample-request/diabetic-retinopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Diabetic Retinopathy: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Diabetic Retinopathy- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. KSI-301: Kodiak Sciences
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. RGX 314: Regenxbio Inc
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. OTX-TKI: Ocular Therapeutix
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Diabetic Retinopathy Key Companies
21. Diabetic Retinopathy Key Products
22. Diabetic Retinopathy- Unmet Needs
23. Diabetic Retinopathy- Market Drivers and Barriers
24. Diabetic Retinopathy- Future Perspectives and Conclusion
25. Diabetic Retinopathy Analyst Views
26. Diabetic Retinopathy Key Companies
27. Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Diabetic Retinopathy Pipeline, Clinical Trials Assessment, NDA Approvals 2023 (Updated) | Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ing here
News-ID: 3136834 • Views: …
More Releases from DelveInsight Business Research
Niemann-Pick Type C Pipeline Report Showcases Emerging Drugs and Leading Compani …
DelveInsight's, "Niemann Pick C Disease Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 15+ pipeline drugs in Niemann Pick C Disease pipeline landscape. It covers the Niemann-Pick Type C pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Niemann-Pick Type C pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this…
Pemphigus Vulgaris Market Positioned for Accelerated Development Through 2034, D …
DelveInsight's "Pemphigus Vulgaris Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Pemphigus Vulgaris, historical and forecasted epidemiology as well as the Pemphigus Vulgaris market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Pemphigus Vulgaris market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pemphigus Vulgaris Market Forecast
https://www.delveinsight.com/sample-request/pemphigus-vulgaris-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Osteogenesis Imperfecta Market to Evolve Rapidly Over the Next Decade by 2034, D …
The Osteogenesis Imperfecta market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Osteogenesis Imperfecta pipeline products will significantly revolutionize the Osteogenesis Imperfecta market dynamics.
DelveInsight's "Osteogenesis Imperfecta Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Osteogenesis Imperfecta, historical and forecasted epidemiology as well as the Osteogenesis Imperfecta market trends in the United…
Myopic Macular Degeneration Market Insights Highlight Expanding Outlook Till 203 …
DelveInsight's "Myopic Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myopic Macular Degeneration, historical and forecasted epidemiology as well as the Myopic Macular Degeneration market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Myopic Macular Degeneration, offering comprehensive insights into the Myopic Macular Degeneration revenue trends,…
More Releases for Diabetic
Diabetic Socks Market Dynamics Shaped by Rising Diabetic Population - Persistenc …
The diabetic socks market is gaining significant traction worldwide, driven by the rising prevalence of diabetes and related complications such as diabetic neuropathy and foot ulcers. Designed specifically to cater to the needs of diabetic patients, these socks play a crucial role in foot protection by preventing blistering, reducing moisture accumulation, and providing cushioning to minimize the risk of ulcers. This article delves deeply into the diabetic socks market, exploring…
Leading Element Driving Change in the Diabetic Footwear Market in 2025: Rising D …
Which drivers are expected to have the greatest impact on the over the diabetic footwear market's growth?
The surge in people with diabetes will spur the expansion of the diabetic footwear market in the future. Diabetes, characterised by high blood sugar levels, is a long-term health issue. Diabetic footwear can prevent severe foot-related issues caused by diabetes and offer several advantages such as enhanced blood flow, ample space for the toes,…
Diabetic Food Market
Future Market Insights (FMI) delivers key insights on the global diabetic food market in its latest report titled “Diabetic Food Market: Global Industry Analysis and Opportunity Assessment, 2014 – 2020”. The global diabetic food market is expected to amplify at a CAGR of 5.9% during the forecast period in terms of value due to various factors, regarding which FMI offers fundamental insights in detail in this report.
On the basis of…
Diabetic Food Market
Diabetes refers to a metabolic disease which leads to high blood sugar levels. The main cause behind diabetes is the insufficient insulin or no response in the body cells where the insulin is produced. Diabetic foods are dietary products rich in carbohydrates and sugar content. They help in controlling rising blood glucose. Diabetic food is low in calorie sweeteners and diet beverages. These products are consumed by diabetic patients and…
Demand for Diabetic Socks Due to Rising Prevalence of Diabetic Neuropathy Expect …
According to the latest market report published by Persistence Market Research titled ‘Diabetic Socks Market: Global Industry Analysis 2012-2016 and Forecast 2017-2025,’ the global diabetic socks market is expected to expand at a CAGR of approximately 4.8% during the forecast period 2017-2025.
To know key findings Request Sample Report @: https://www.persistencemarketresearch.com/samples/19282
Global Diabetic Socks Market: Factors Impacting the Market
The primary factors driving the growth of the global diabetic socks market are increasing…
Diabetic Food Market -
In recent times, diabetes has emerged as one of the most challenging health conditions across the world. According to the WHO, a total of 415 million cases of diabetes were reported globally in 2015. The count is rising at an alarming rate and is expected to reach 642 million in the next 25 years. Till now no medication has been found that can completely cure diabetes. It can only be…
